Viridian Therapeutics, Inc.\DE
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
VRDN chart
What traders are saying about $VRDN
Latest postsViridian Therapeutics, Inc.\DE news
- Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
proactiveinvestors.com ·
- Viridian Reports Positive Phase 1 Results for VRDN-008
TipRanks ·
- Viridian Therapeutics, Inc. (VRDN) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
Yahoo Finance ·
- A potential autoimmune treatment could be given every 8 weeks
Stock Titan ·
- Viridian Therapeutics, Inc.\DE ($VRDN) CEO 2025 Pay Revealed
Quiver Quantitative ·
- Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history
Yahoo Finance Singapore ·
- Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut With ...
Yahoo Finance ·
- Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Yahoo Finance ·
- Healthy volunteers took part in the drug study Viridian will discuss Nov. 9
Stock Titan ·
- Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
Yahoo Finance ·
- Viridian Therapeutics (NasdaqCM:VRDN) Stock Forecast & Analyst Predictions
Simply Wall St ·
Viridian Therapeutics, Inc.\DE key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$342.6M | -$269.9M | -$237.7M | -$129.9M |
| Diluted EPS | – | – | $-5.31 | $-4.05 |
| Total assets (year end) | $899.4M | $742.4M | $490.4M | $435.1M |
| Cash and equivalents (year end) | $212.4M | – | – | – |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Viridian Therapeutics, Inc.\DE
- Ticker
- VRDN (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1590750
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
Frequently asked questions
What exchange is Viridian Therapeutics, Inc.\DE listed on?
Viridian Therapeutics, Inc.\DE trades on the Nasdaq under the ticker symbol VRDN.
What industry is Viridian Therapeutics, Inc.\DE in?
Viridian Therapeutics, Inc.\DE is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Viridian Therapeutics, Inc.\DE headquartered?
Viridian Therapeutics, Inc.\DE's business address on file with the SEC is in Waltham, MA.
When does Viridian Therapeutics, Inc.\DE's fiscal year end?
Viridian Therapeutics, Inc.\DE's fiscal year ends on December 31.
How much revenue did Viridian Therapeutics, Inc.\DE report?
Viridian Therapeutics, Inc.\DE reported $4.0M in revenue for calendar year 2017, according to its SEC filings.